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Abstract
Rod-cone dystrophy, also known as retinitis pigmentosa (RP), is the most common inher-
ited degenerative photoreceptor disease, for which no therapy is currently available. The
P23H rat is one of the most commonly used autosomal dominant RP models. It has been
created by incorporation of a mutated mouse rhodopsin (Rho) transgene in the wild-type
(WT) Sprague Dawley rat. Detailed genetic characterization of this transgenic animal has
however never been fully reported. Here we filled this knowledge gap on P23H Line 1 rat
(P23H-1) and provide additional phenotypic information applying non-invasive and state-of-
the-art in vivo techniques that are relevant for preclinical therapeutic evaluations. Trans-
gene sequence was analyzed by Sanger sequencing. Using quantitative PCR, transgene
copy number was calculated and its expression measured in retinal tissue. Full field electro-
retinography (ERG) and spectral domain optical coherence tomography (SD-OCT) were
performed at 1-, 2-, 3- and 6-months of age. Sanger sequencing revealed that P23H-1 rat
carries the mutated mouse genomic Rho sequence from the promoter to the 3’ UTR. Trans-
gene copy numbers were estimated at 9 and 18 copies in the hemizygous and homozygous
rats respectively. In 1-month-old hemizygous P23H-1 rats, transgene expression repre-
sented 43% of all Rho expressed alleles. ERG showed a progressive rod-cone dysfunction
peaking at 6 months-of-age. SD-OCT confirmed a progressive thinning of the photoreceptor
cell layer leading to the disappearance of the outer retina by 6 months with additional mor-
phological changes in the inner retinal cell layers in hemizygous P23H-1 rats. These results
provide precise genotypic information of the P23H-1 rat with additional phenotypic charac-
terization that will serve basis for therapeutic interventions, especially for those aiming at
gene editing.
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Introduction
Rod-cone dystrophy, also known as retinitis pigmentosa (RP), is a clinically and genetically
heterogeneous group of progressive inherited retinal disorders, which often start with night
blindness and lead to visual field constriction, secondary macular involvement and in many
cases results in loss of central vision and complete blindness [1]. RP occurs in 1 of 4,000 births
and affects more than 1 million individuals worldwide [1]. The mode of inheritance can be au-
tosomal dominant (ad), autosomal recessive (ar), or X-linked. Currently, there is no treatment
for this disease but various therapeutic strategies are under investigation.
Mutations in the rhodopsin-encoding gene (RHO; MIM# 180380) were the first molecular
defects identified in RP [2–5]. More than 100 different RHOmutations have been reported to
date, which account for 30–40% of autosomal dominant RP (adRP) cases in United States [1]
and 16% in France [6]. Furthermore, mutations in 25 other genes cause adRP (http://www.sph.
uth.tmc.edu/Retnet/, last accessed date on December 16th, 2014) with mutations in RHO being
the most prevalent [6, 7]. RHO encodes for the rod-specific protein rhodopsin, which belongs
to the superfamily of 7 transmembrane G-protein—coupled receptors. Rhodopsin consists of
an apoprotein (opsin) that is covalently bound to a small conjugated chromophore (11-cis-reti-
nal), derived from vitamin A. Upon light absorption, the chromophore isomerizes into all-
trans-retinal, with subsequent rhodopsin conformational changes leading to the activation of
the phototransduction cascade [8].
The P23H exchange in RHO is the most prevalent cause of RP in the United States [3]. In
this country, this mutation alone accounts for about 12% of adRP cases and about a third of
those with a dominant RHOmutation [9]. Previous studies have suggested that the P23H mu-
tant protein is misfolded, retained in the endoplasmic reticulum (ER) and unable to bind 11-
cis-retinal [10–12]. The misfolded RHO can be degraded through the ubiquitin-proteasome
system or aggregates in the cytoplasm [13, 14]. In order to better understand the disease and its
pathogenic mechanisms, P23H transgenic albino rats were generated by incorporating a
C57BL/6J mouse P23H mutated transgene into a Sprague-Dawley wild-type (WT) rat back-
ground. The transgene used was cloned from C57BL/6J mice. It was made from the entire wild
type 15kb of the mouse rhodopsin genomic fragment (called lambda 11) as indicated in Al-
Ubaidi et al. (1990) [15]. The 15 kb genomic fragment lacking the lambda arms with the P23H
mutation was used to generate the rat models. It was initially generated to create a mouse
model and therefore few variants were inserted in order to screen the mouse transgene in the
presence of the wild-type mouse copy. Three lines of P23H transgenic albino rats were generat-
ed with this transgene: one represents a fast degeneration (Line 1), one a slower degeneration
(Line 3) and one a very slow degeneration model (Line 2). All three lines suffer from a progres-
sive rod degeneration initially associated with normal cone function [16] (UCSF School of
Medicine, http://www.ucsfeye.net/mlavailRDratmodels.shtml). These phenotypes are consis-
tent with the clinical findings in patients carrying the P23H RHOmutation. Photoreceptor loss
correlates with full field electroretinogram (ERG) abnormalities in dark adapted (i.e., scotopic)
conditions. Under these conditions, the a-wave amplitude, reflects rod photoreceptor hyperpo-
larization upon light stimulation, whereas the b-wave represents the subsequent bipolar cell de-
polarization upon signal transmission from the photoreceptors. Both a- and b- waves of the
P23H rat are dramatically reduced over time. In light adapted (i.e., photopic) conditions, the b-
wave is normal until the outer nuclear layer (ONL), containing photoreceptor nuclei, thins be-
yond 50% [17]. In addition to photoreceptor degeneration, there is a subsequent reduction in
rod bipolar dendrites [18] and a substantial loss of retinal ganglion cells [19, 20]. By reproduc-
ing the clinical signs observed in patients, the P23H rat model is very valuable for testing thera-
peutic approaches for adRP. Nevertheless, the genotype of this popular animal model has not
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been fully reported thus far. In this study, we focused on the P23H Line 1 (P23H-1) rat model
frequently used due to its fast and sequential degeneration affecting first rod and then cone
photoreceptors [17]. We established the exact sequence of the mutated transgene and report
copy number and corresponding expression level. In addition, we sought to more precisely
document the kinetics of retinal abnormalities applying two in vivo techniques, ERG and spec-
tral-domain optical coherence tomography (SD-OCT), a high resolution imaging technique,
allowing monitoring the thickness of retinal layers. Both of these in vivo assessment techniques
are routinely applied to patients with retinal disease.
Material and Methods
Animals
Transgenic homozygous P23H-1 rats were obtained from the laboratory of Matthew LaVail
(UCSF School of Medicine, http://www.ucsfeye.net/mlavailRDratmodels.shtml) and were
crossed with WT albino Sprague-Dawley rats purchased from Janvier (Le Genest-Saint-Isle,
France) to produce hemizygous P23H-1 rats. Animals were housed with a 12-hour dark/light
cycle with food (standard diet R0425, Scientific Animal Food & Engineering, Augy, France)
and water available ad libitum.
Light level was measured in the cage with a luxmeter (Illuminance Meter T10, Konica Min-
olta, Osaka, Japan) and varied between 20 and 180 lux depending on the position of the rat in
the cage and the position of the cage in the rack. For more consistence, WT and hemizygous
P23H-1 rats of a same group were housed on the same row.
Ethic statements
All procedures were carried out according to the guidelines on the ethical use of animals from
the European community council directive (86/609/EEC) and were approved by the French
minister of agriculture (OGM agreement 5080).
Sanger sequencing of hemizygous P23H-1 rats
Genomic DNA (gDNA) was isolated from rat tails using a kit (DNeasy Blood & Tissue Kit,
Qiagen, Venlo, The Netherlands). Nineteen couples of primers were designed to amplify the
mouse Rho gene (NC_000072.6, gene structure depicted in Fig 1A) including the c.68C>A, p.
Pro23His mutation (P23H mutated mouse Rho transgene) (Table 1). Amplicons were of 500-
800-base-pair length covering the promoter region to the 3’ untranslated region (UTR) of the
gDNA of mouse Rho in the P23H-1 rat. The following PCR parameters were applied: 15 min at
95°C for denaturation, 35 cycles of 45 sec at 95°C, 1 min at 58°C, and 30 sec at 72°C, and for
final extension 10 min at 72°C (HOT FIREPol, Solis Biodyne, Tartu, Estonia). WT rat gDNA
was used as control. When it was not possible to design probes to specifically amplify the P23H
mutated mouse transgene, adjacent mouse-specific flanking primers were used to amplify larg-
er genomic regions encompassing the fragment of interest (amplicon 6, 9, 10 and 17). The fol-
lowing PCR parameters were then applied: 15 min at 95°C for denaturation, 35 cycles of 45 sec
at 95°C, 1 min at 58°C, and 1 min at 72°C, and for final extension 10 min at 72°C (HOT FIRE-
Pol). The specificity of PCR products was checked for correct size by electrophoresis on 2%
agarose gels, subsequently Sanger sequenced with a sequencing mix (BigDyeTerm v1.1 Cycle-
Seq kit, Applied Biosystems, Courtaboeuf, France) and primers (Table 1), on an automated
48-capillary sequencer (ABI 3730 Genetic analyzer, Applied Biosystems, Life technologies,
Carlsbad, California, USA). Sequences were compared to the reference sequence
(NC_000072.6) using appropriate software (SeqScape, Applied Biosystems).
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Transgene copy number quantification by quantitative PCR
Quantitative PCR (qPCR) to identify transgene copy number was adapted from Ballester and
co-workers [21]. qPCR was conducted on 25ng of gDNA from 5 animals per genotype (WT,
hemizygous P23H-1 and homozygous P23H-1 rats to check the validity of the method) with
triplicate in a 20μl reaction using a kit (Taqman PCR Universal Master Mix no AmpErase UNG
and the StepOnePlus Real-Time PCR system,both from Applied Biosystems). Probes (Applied
Biosystems) were specific to the P23H mutated mouse transgene or the rat Rho gene
(NC_005103.4). The final concentration of primers (Sigma-Aldrich, Saint-Louis, Missouri,
USA) was 200 mM each and 250 nM for the probe (listed on Fig 2A). The qPCR was run using
the following amplification parameters: 10 min at 95°C and 40 cycles of 15 sec at 95°C and 1
min at 60°C. Relative quantification of endogenous rat Rho and P23Hmutated mouse Rho trans-
gene was performed using the 2-ΔΔCt method with the rat beta-actin gene for normalization.
RNA extraction, reverse transcription and transgene expression
measurement by quantitative PCR
Total RNA was isolated from 1-month-old rat retinas using a kit (RNeasy Mini Kit, Qiagen),
followed by a complementary treatment with RNase-free DNase (Qiagen) to ensure the
Fig 1. P23HmutatedmouseRho transgene. (A) Schematic drawing of the sequence: the transgene comprises the gDNA of mouse Rho from the promoter
to the 5’UTR, encompassing the exons and introns. (B) Exon 1 first 40 codon sequence: the c.68C>Amissense mutation leading to the p.Pro23His exchange
is framed, and the 2 variations surrounding the mutation are underlined.
doi:10.1371/journal.pone.0127319.g001
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absence of gDNA. RNA integrity was verified by agarose gel electrophoresis. One microgram
of total RNA was reverse-transcribed with oligo-dT using a transcriptase (Superscript II Re-
verse Transcriptase, Invitrogen, Life technologies, Carlsbad, California, USA) following the
manufacturer's instructions. qPCR was conducted on cDNA of 5 animals per genotype (WT
and hemizygous P23H-1 rats) using a kit (StepOnePlus Real-Time PCR system, Applied Bio-
systems) and 2 couples of specific primers for each P23H mutated mouse Rho transgene and
endogenous rat Rho, and one couple of primers for rat beta-actin (Sigma-Aldrich, listed on Fig
3A). The equivalent of 1.25 ng of cDNA was used per well as template for qPCR reactions with
Table 1. P23Hmutated mouse transgene Sanger sequencing primers.








































P23H Line 1 Rat Model Characterization
PLOS ONE | DOI:10.1371/journal.pone.0127319 May 26, 2015 5 / 21
a SYBR green master mix (Power SYBR green PCR Master Mix, Applied Biosystems). Each
condition was performed in triplicates; Ct values were obtained with a software (ABI 7500,
v.2.0.6, Applied Biosystems). Comparative ΔΔCt method with rat beta-actin as a housekeeping
gene was used to determine the relative P23H mRNA from mouse Rho transgene versus endog-
enous rat Rho.
Fig 2. P23HmutatedmouseRho transgene copy number. (A) Target and sequence of primers and probes used for qPCR, FAM: 6-carboxyfluorescein
and TAM: tetramethylrhodamine. (B) WT endogenous rat Rho (light grey) and P23Hmutant mouse Rho (dark grey) copy numbers were evaluated by qPCR
and 2-ΔΔCt method for WT (WT), hemizygous P23H-1 (P23H hemi) and homozygous P23H-1 (P23H homo) rats. All experiments were conducted on the
gDNA of 5 rats per group. Three asteriks (***) indicate a p value of <0.001, error bars represent standard errors.
doi:10.1371/journal.pone.0127319.g002
P23H Line 1 Rat Model Characterization
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Full field electroretinogram (ERG)
ERG was performed at age 1, 2, 3, 6 and 7 months on 12 WT and 14 hemizygous P23H-1 rats.
After overnight dark adaptation, rats were anesthetized with ketamine (100 mg/kg) and xyla-
zine (10 mg/kg). Eye drops were used to dilate the pupils (0.5% tropicamide) and anesthetize
the cornea (0.4% oxybuprocaine chlorhydrate). Body temperature was maintained at 37°C
using a circulating hot water heating pad. Upper and lower lids were retracted to keep the eyes
open and bulging. Custom-made gold contact lens electrodes were placed on the corneal sur-
face to record the ERG (VisioSytem, SIEM Bio-medicale, Nîmes, France). Needle electrodes
Fig 3. P23HmutatedmouseRho transgene expression. (A) Target and sequence of primers used for RT-qPCR. (B) WT endogenous rat Rho (light grey)
and P23Hmutant mouse Rho (dark grey) relative expressions were evaluated by qPCR and 2-ΔΔCt method for 1-month-old WT (WT) and hemizygous P23H-
1 (P23H hemi) rat retinas. In 1-month-old WT rats endogenous Rho expression was assessed at 100%. All experiments were conducted on the retinal cDNA
of 5 rats per group. Three asteriks (***) indicate a p-value of <0.001, error bars represent standard errors.
doi:10.1371/journal.pone.0127319.g003
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placed subcutaneously in cheeks served as reference and a needle electrode placed in the back
served as ground. Recordings were made from both eyes simultaneously. The light stimulus
was provided by a Ganzfeld stimulator (Visiosystem, SIEM Bio-medicale). Responses were am-
plified and filtered (1 Hz-low and 300 Hz-high cut off filters) with a 1 channel DC-/AC-ampli-
fier. Four levels of stimulus intensity ranging from 1.9 cd.s.m-² to 12 cd.s.m-² were used for the
dark-adapted ERG recording. Each scotopic ERG response represents the average of 5 re-
sponses from a set of 5 flashes of stimulation. To isolate cone responses a 5-minute light adap-
tation at 20 cd.m-2 was used to saturate rod photoreceptors. A 12 cd.s.m-² level of stimulus
intensity was used for the light-adapted ERGs. The light-adapted ERGs were recorded on the
same rod-suppressive white background as for the light adaptation. Each cone photopic ERG
response represents the average of 10 responses. The major components of the ERG were mea-
sured conventionally [22]. All comparisons were done at 12 cd.s.m-² of intensity (scotopic and
photopic responses).
Spectral domain optical coherence tomography (SD-OCT)
SD-OCT was performed at age 1, 2, 3 and 6 months on 9 WT and 9 hemizygous P23H-1 rats.
Rats were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg). Eye drops were
used to dilate the pupils (0.5% tropicamide) and eye dehydration was prevented by regular in-
stillation of sodium chloride drops. SD-OCT images were recorded for both eyes using a spec-
tral domain ophthalmic imaging system (Bioptigen, Inc., Durham, NC, USA). We performed
rectangular scans consisting of a 2 mm by 2 mm perimeter with 1000 A-scans per B-scan with
a total of 100 B-scans. Scans were obtained first while centering on the optic nerve, and then
with the nerve displaced either temporally/nasally/dorsally or ventrally. SD-OCT scans were
exported from InVivoVue as AVI files. These files were loaded into ImageJ (version 1.47; Na-
tional Institutes of Health, Bethesda, MD, USA) where they were registered using the Stackreg
plug-in. If the optic nerve was placed temporally/nasally, three B-scans at the level of the nerve
were added, and measurements were performed 800 μm away from the optic disc, on each side.
In the case where the optic nerve was placed dorsally/ventrally, 3 B-scans placed 800 μm away
from the optic disc were added to perform the measurements. Thickness from the following
layers were measured: ONL, outer plexiform layer (OPL), inner nuclear layer (INL), a complex
comprising inner plexiform layer (IPL), ganglion cell layer (GCL) and nerve fiber layer (NFL)
that we called IPL+GCL+NFL, and the whole inner retinal layers comprising OPL, INL and
IPL + GCL + NFL
Statistical analyses
Statistical analyses were performed using the Mann-Whitney U test on statistical software
(SPSS, version 19.0 Inc, Chicago, Illinois, USA). For transgene copy number quantification by
qPCR, each gene copy number in the same group, and copy number of the same gene in each
group, were compared. For transgene expression quantification by RT-qPCR, each gene relative
expression in the same group, and relative expression of the same gene in each group were com-
pared. For scotopic ERG, a- and b-wave amplitudes and implicit times of maximum intensity
(cd.s.m-²) stimulus responses were compared betweenWT and hemizygous P23H-1. For phot-
opic ERG, a-waves were not analyzed because of the low amplitudes and high variability in re-
cordings. However, b-wave amplitude and implicit time were compared betweenWT and
hemizygous P23H-1 rats. To compare rod and cone dysfunction, differences betweenWT and
hemizygous P23H-1 b-wave amplitude at each time were performed and compared between sco-
topic and photopic conditions withWilcoxon signed-rank test. For SD-OCT, in each group,
comparison of thickness for each layer at each time point between the 4 positions of acquisitions
P23H Line 1 Rat Model Characterization
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(temporal, nasal, dorsal, and ventral) revealed no statistical difference; therefore these values
were combined. Then, all thickness values for each layer at a given time were compared between
WT and hemizygous P23H-1 groups. Finally, Spearman rank correlation coefficients were calcu-
lated for P23H-1 rats on the means of scotopic a-wave amplitude for a stimulation of 12 cd.s.m-²
and ONL thickness, scotopic a-wave and b-wave amplitudes for a stimulation of 12 cd.s.m-², and
scotopic a-wave and b-wave implicit times for a stimulation of 12 cd.s.m-².
Results
P23H-1 rat genotyping
Transgene sequence. We first investigated the transgene sequence of the P23H-1 rat
model thought to be a mouse P23H mutated allele inserted in a WT rat background. Sanger se-
quencing with mouse Rho specific primers revealed that this transgene contains the entire
mouse opsin (Rho) genomic DNA (gDNA) from the promoter to the 3’UTR encompassing all
exons and introns (Fig 1A). We confirmed the presence of the c.68C>A, p.Pro23His mutation.
Two synonymous variations surrounding the P23H exchange (Fig 1B), were identified in addi-
tion to other variations in the promoter or 5’UTR (Table 2).
Quantification of P23H transgene copy number. P23H mutated mouse transgene copy
number was determined in both hemizygous and homozygous P23H-1 rats. Rat beta-actin nor-
malization allowed us to determine the endogenous rat Rho copy number to be 2 copies for
both hemizygous and homozygous P23H-1 rats, validating our method (Fig 2B). The P23H
transgene copy number was statistically different in the different groups. Eighteen copies were
counted for homozygous P23H-1 rats and 9 for hemizygous P23H-1 animals. As expected, no
P23H mutated mouse transgene copy was found in WT rats (Fig 2B).
Quantification of P23H transgene expression. Endogenous rat Rho (rRHO) expression
in 1-month-old WT rats was set at 100%. As expected, there was no P23H transgene expression
in this group (Fig 3B). However, in 1- month-old hemizygous P23H-1 rats, endogenous wild-
type Rho expression was reduced to 66% of age-matched WT (p<0.001). The mutated allele
represented 43% of overall Rho expressed alleles, being also 20% lower than endogenous wild-
type Rho (p<0.001).
P23H-1 rat phenotyping
Full-field ERG recordings. ERG responses of WT and hemizygous P23H-1 rats were re-
corded at 1-, 2-, 3-, 6- and 7-months of age under scotopic and photopic conditions, allowing
us to estimate respectively rod and cone photoreceptor function. Results are displayed for 12 cd.
s.m-² stimulus intensity. Under scotopic conditions, amplitudes of both a- and b-waves were re-
duced as early as 1 month after birth in hemizygous P23H-1 rats compared to WT rats
(p<0.001 at each age). This decrease is accentuated with age leading to a flat a-wave at 6 months
and an 88% reduction in b-wave amplitude at 7 months (137μV for hemizygous P23H-1 rats
and 1216 μV for WT rats, Fig 4A–4C). Moreover, b-wave implicit time is increased starting at 1
month of age (p<0.01), with a maximum of 35% increase reached at 7 months (p<0.001, Fig
4A and 4E). In contrast, there is no significant change in implicit time of a-wave (Fig 4A and
4D). Taken together, these results indicate rod photoreceptor dysfunction progressing with age.
In photopic conditions, a-wave amplitudes and implicit times are difficult to reliably mea-
sure due to their small amplitudes both in WT and mutant rats. Nevertheless, b-wave ampli-
tudes and implicit times are well defined. As observed under scotopic conditions, b-wave
amplitude is reduced from the first month of age in mutant compared to WT animals
(p<0.001 at each age), and this decrease progresses with age reaching 78% of diminution be-
tween hemizygous P23H-1 andWT rats at 7 months of age. Implicit time also increases
P23H Line 1 Rat Model Characterization
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starting at 1 month with a maximum increase of 46% reached at 7 months of age (Fig 5A–5C).
When comparing a- and b-wave amplitude, the Spearman rank correlation coefficient was ρ =
0.87 (p<0.0001) on WT animals and ρ = 0.83 (p<0.0001) on P23H-1 hemizygous rats while
comparing the a- and b- wave implicit time ρ = 0.47 (p = 0.00261) for WT animals and ρ =
0.627 (p<0.0001) for P23H-1 hemizygous rats.
Retinal layers assessment of the P23H-1 rats by SD-OCT. Representative SD-OCT im-
ages from 1-, 2-, 3- and 6-month hemizygous P23H-1 rats, compared to WT retinas, show a
progressive thinning of the ONL (composed of rod and cone photoreceptor nuclei, described
in Fig 6A and depicted by white arrows in Fig 6B). WT and hemizygous P23H-1 rat retinal lay-
ers (ONL, OPL, INL, IPL+GCL+NFL and inner retinal layers, described in Fig 6A) are all
Table 2. P23Hmutated mouse transgene variations.
Nomenclature Type Description
c.1-1448T>C Upstream gene variant rs31513717
c.1-1433A>G Upstream gene variant rs31513719
c.1-1290A>G Upstream gene variant rs31003645
c.1-1275A>G Upstream gene variant rs31513722
c.1-1201T>C Upstream gene variant rs31514804
c.1-1181A>G Upstream gene variant never described
c.1-1174dup Upstream gene variant never described
c.1-1139C>T Upstream gene variant rs31509484
c.1-1048A>G Upstream gene variant rs3666783
c.1-991G>A Upstream gene variant rs31509489
c.1-895T>A Upstream gene variant rs31509491
c.1-894del Upstream gene variant never described
c.1-700G>T Upstream gene variant rs30903457
c.1-546C>T Upstream gene variant never described
c.1-540dup Upstream gene variant never described
c.1-357A>G Upstream gene variant rs214120882
c.66C>T, p.Ser22Ser Synonymous never described
c.68C>A, p.Pro23His Missense Dryja, 1990, Nature
c.102A>T,p.Pro34Pro synonymous never described
c.1047+190G>A 3'UTR variant rs31514859
c.1047+210T>C 3'UTR variant rs31514861
c.1047+513T>C 3'UTR variant rs21232304
c.1047+554A>G 3'UTR variant rs237469398
c.1047+652T>G 3'UTR variant rs250121950
c.1047+656A>G 3'UTR variant rs115937375
c.1047+665_c.1047+675dup 3'UTR variant rs262701018
c.1047+666A>G 3'UTR variant rs250907798
c.1047+841C>T 3'UTR variant rs239300315
c.1047+1249C>T 3'UTR variant rs234137219
c.1047+1469C>T 3'UTR variant rs31515781
c.1047+1531G>A 3'UTR variant rs31515783
c.1047+1553A>G 3'UTR variant rs216330615
c.1047+1591_c.1047+1592insT 3'UTR variant rs217122073
c.1047+1629C>T 3'UTR variant rs31516697
c.1047+2052G>A 3'UTR variant rs107847221
doi:10.1371/journal.pone.0127319.t002
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Fig 4. Scotopic ERG phenotype. Dark-adapted ERG series were obtained from representative WT (n = 12, blue line) and hemizygous P23H-1 (n = 14, red
line) rats at 1,2,3,6 and 7 months of age and a 12 cd.s.m-² stimulus intensity. (A) Representative waveforms, as a function of age. The scale marks indicate
50ms (time in abscissa) and 300μV (amplitude in ordinate) (B-C) Mean maximum amplitudes of a-wave (B) and b-wave (C) with increasing age. (D-E) Mean
implicit times of a-wave (D) and b-wave (E) with increasing ages of rats. Asteriks indicate a significant test (** for p<0.005 and *** for p<0.001) betweenWT
and hemizygous P23H-1 responses, error bars represent standard errors.
doi:10.1371/journal.pone.0127319.g004
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Fig 5. Photopic ERG phenotype. Light-adapted ERG series were obtained from representative WT (n = 12, blue line) and hemizygous P23H-1 (n = 14, red
line) rats at 1,2,3,6 and 7 month of age and at 12 cd.s.m-² stimulus intensity after a 5-minute light adaptation at 20 cd.m-². (A) Representative waveforms, as a
function of age. The scale marks indicate 50ms (time in abscissa) and 100μV (amplitude in ordinate) (B-C) Mean maximum amplitudes (B) and implicit times
(C) of b-wave in time. Because of the limit of sensitivity of the method, the a-wave component is not plotted. Asteriks indicate a significant test (** for p<0.005
and *** for p<0.001) betweenWT and hemizygous P23H-1 rats’ responses, error bar represents standard errors.
doi:10.1371/journal.pone.0127319.g005
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thinned between 1 and 6 months of age (Fig 7 and Table 3). When studied separately, some
changes appear between WT and hemizygous P23H-1 rat retinal layers. Hemizygous P23H-1
rat ONL thins with aging to finally reach 86% of decrease at 6-months-of-age when WT rat
ONL is reduced by 27% (p<0.001, Fig 7A and Table 3). One-month hemizygous P23H-1 rat
inner retina is thinner than WT, and this difference is maintained but not modified with aging
(Fig 7B and Table 3). If layers composing the inner retina are studied separately, changes ap-
pear in the OPL. Hemizygous P23H-1 rat OPL are decreased at 3-months (p<0.005) and
6-months (p<0.001) of age when compared to WT (Fig 7C and Table 3). Inner nuclear layer
from 1-month hemizygous P23H-1 rat is thinner than WT (p<0.05), but this difference disap-
pears with aging (Fig 7D and Table 3). As observed for inner retina, 1-month hemizygous
P23H-1 rat IPL + GCL + NFL is thinner than WT, and this difference remains constant with
aging (Fig 7E and Table 3).
Discussion
The present study reports the exact sequence, copy number and retinal expression level of the
P23H mutated transgene in the P23H-1 rat model, using Sanger sequencing, qPCR and RT-
qPCR analysis. Furthermore it documents in greater detail the disease course in this rat model
with functional and structural phenotypic assessment using in vivo evaluation by ERG and
SD-OCT.
Fig 6. SD-OCT retinal thickness layers and retinal morphology (A) Outer nuclear layer (ONL), outer plexiform layer (OPL), inner nuclear layer (INL), a
complex comprising inner plexiform layer (IPL), ganglion cell layer (GCL) and nerve fiber layer (NFL) called IPL+GCL+NFL, and inner retinal layer thickness
are measured at 800 μm of the optic nerve on SD-OCT images (B) Representative SD-OCT section of a 6-month-old WT rat and 1-, 2-, 3-, and 6-month-old
hemizygous P23H-1 rats. White arrows depict ONL. Scale bar: 200μm.
doi:10.1371/journal.pone.0127319.g006
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P23H rat models were developed for translational research and study photoreceptor rescue
strategies [23, 24]. By reproducing the degeneration observed in patients [19], these animal
models are extremely helpful for therapeutic approaches for adRP, a yet incurable disease.
P23H-1 rat model is the most commonly used model since it carries the most frequent
Fig 7. SD-OCT retinal thickness layer monitoring. Retinal layer thicknesses are measured at 800 μm of the optic nerve on SD-OCT images and compared
to WT (blue line) and hemizygous P23H-1 (red line) at 1, 2, 3 and 6 months of age. (A) Outer nuclear layer (ONL), (B) inner retinal layer, (C) outer plexiform
layer (OPL), (D) inner nuclear layer (INL), (E) a complex comprising inner plexiform layer (IPL), ganglion cell layer (GCL) and nerve fiber layer (NFL) called
IPL+GCL+NFL. Asteriks indicate the following p values: * for p<0.05 and *** for p<0.001, error bars represent standard errors.
doi:10.1371/journal.pone.0127319.g007
P23H Line 1 Rat Model Characterization
PLOS ONE | DOI:10.1371/journal.pone.0127319 May 26, 2015 14 / 21
mutation in adRP in the US [1] and displays relatively fast degeneration over 6 months
(http://www.ucsfeye.net/mlavailRDratmodels.shtml). This allows an easy documentation of
the phenotype and fast monitoring of putative therapeutic rescue. Moreover, hemizygous ani-
mals were preferred to homozygous since it was supposed to more closely resemble the
human autosomal dominant genetic conditions with one mutated allele and present a slower
degeneration, more suitable for translational research. Several strategies of photoreceptor
[25] and Muller glial cell [26] transplantation or administration of anti-apoptotic [27, 28],
heat shock response activator [29] or enhancer [30], anti-aggregating [31], or neuroprotective
[32, 33] molecules and chaperones [34] have been attempted to slow the degeneration and
demonstrated partial preservation of photoreceptor morphology and function. However,
treatment efficacy was evaluated in comparing treated and untreated animals less than 1
month after treatment, or after 6 months of age, a time point at which photoreceptor degener-
ation is almost complete. RNA-targeted therapy by gene silencing using ribozymes directed
against the mouse transgene in P23H Line 3 rat model has also been attempted [23, 24, 35]
and revealed some preservation of the ONL thickness. Functional characterization by ERG
shows a slight increase in response amplitude in treated versus untreated eyes after 3 months
of age [23, 35]. These approaches indicate that genetic-targeted therapies including selective
mutated allele suppression or gene replacement at the DNA or RNA level could be tested. De-
spite multiple studies that attempt therapeutic intervention in the P23H model, the genotype
of this animal model was not yet fully available. We first addressed this question by character-
izing the exact sequence of the mutated transgene in P23H-1 rats. Our data confirmed that
the transgene contains the entire mouse Rho genomic DNA sequence including the promoter,
all 5 exons and 4 introns with the P23H mutation as well as most of the 3’UTR. Variations
were also identified in the promoter, exon 1 and 3’UTR. These include [c.66C>T, p.Ser22Ser]
and [c.102A>T, p.Pro34Pro] (Fig 1B). These variations are silent and most likely predicted to
be benign but will need to be taken into account while investigating genome editing strategies.
Furthermore, we investigated transgene copy numbers and identified that homozygous and
hemizygous P23H-1 rats carry 18 and 9 copies of the P23H transgene, respectively. This is co-
herent with the Mendelian transmission of this transgene with half of the copies of the homo-
zygous in the hemizygous P23H-1 rats supporting a tandem insertion at a unique locus. This
result led us to investigate if all transgene copies were expressed. In 1-month-old hemizygous
P23H-1 rat retinas, WT Rho expression was 66% reduced compared to the age-matched WT
rats. This result was consistent with photoreceptor degeneration due to retinitis pigmentosa
[31]. Interestingly, in 1-month-old hemizygous P23H-1 rats, the mutated allele represented
43% of overall Rho expressed alleles, despite the 9 copies of the transgene. This resembles
Table 3. Retinal layer thicknessmeasured by SD-OCT in WT and hemizygous P23H-1 rats at 1, 2, 3 and 6 months of age.
WT P23H-1
1 month 2 months 3 months 6 months 1 month 2 months 3 months 6 months
ONL 44μm ±3μm 43 μm ±11 μm 36 μm ±2 μm 33 μm ±2 μm 29 μm ±3 μm 23μm ±5 μm 13 μm ±3 μm 3 μm ±2 μm
OPL 8μm ±1 μm 9 μm ±2 μm 7 μm ±3 μm 7 μm ±1 μm 8 μm ±1 μm 8 μm ±2 μm 8 μm ±1 μm 7 μm ±3 μm
INL 19 μm ±3 μm 17 μm ±4 μm 12 μm ±5 μm 13 μm ±2 μm 18 μm ±2 μm 18 μm ±4 μm 14 μm ±2 μm 13 μm ±3 μm
IPL+GCL+NFL 48 μm ±4 μm 47 μm ±4 μm 36 μm ±13 μm 38 μm ±2 μm 43 μm ±3 μm 43 μm ±6 μm 36 μm ±2 μm 34 μm ±2 μm
Inner retinal layers 75 μm ±5 μm 74 μm ±12μm 57 μm ±20 μm 60 μm ±3 μm 69 μm ±3 μm 70 μm ±13 μm 59 μm ±3 μm 53 μm ±3 μm
(mean ± standard deviation; ONL: outer nuclear layer, OPL: outer plexiform layer, INL: inner nuclear layer, IPL: inner plexiform layer, GCL: ganglion cell
layer, NFL: nerve fiber layer)
doi:10.1371/journal.pone.0127319.t003
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what is expected in patients with the P23H mutation, where both normal and mutated alleles
are thought to be expressed at the same levels. This low expression of transgene in hemizy-
gous P23H-1 rats could be due to WT and P23H Rho expression regulation at the mRNA lev-
els, as described in a P23H mouse line with genomic mutated mouse opsin transgene [36].
Intrinsic silencing effect of multiple-copy tandem repeats on transgene expression could also
be an explanation, since transcription inhibition can occur when more than 5 copies of the
transgene are present [37, 38]. Insertion site of the transgene is also important since chroma-
tin structure influences the expression level [39]. This result is favorable for intervention ap-
plying gene therapy, since low level of transcript is more likely to respond to gene silencing at
the mRNA level than an overexpressed transgene. Altogether, our study provides important
details on the P23H-1 rat’s genotype by describing the exact transgene sequence with its
P23H mutation and variations, its copy number and expression. These data can serve basis
for mutated allele specific therapeutic interventions using this model. Nevertheless, we cannot
exclude a drift of the inserted copy number in the various colonies of P23H rat available to
the scientific community and would recommend testing such parameter before attempting
therapeutic studies especially those aiming at genome editing.
Another purpose of this work was to better monitor natural history of the disease applying
functional and high-resolution in vivo phenotyping techniques. Functional characterization of
hemizygous P23H-1 rats revealed reduced rod and cone response amplitudes and delayed im-
plicit time as seen in RP patients [1, 3, 40]. In both scotopic and photopic conditions, hemizy-
gous P23H-1 rats already displayed decreased responses at 1-month, enhanced by aging
especially after 3-months and flatting at 6-months of age. Scotopic responses were more affected
than photopic responses, indicating that rod photoreceptor dysfunction was more severe than
cone photoreceptor dysfunction. These results are concordant with previous observations [17]
and confirmed the usefulness of this model to mimic human disease with rod-cone dystrophy
[1, 3, 40, 41]. Our study also provides retinal thickness monitoring using high resolution imag-
ing with SD-OCT in hemizygous P23H-1 rats. Indeed, this non invasive in vivo technique en-
ables longitudinal studies and now achieves the resolution of histology, without its terminal
nature. Moreover, this alleviates the fixation process on retinal sections, which is a potential
source of variation in structure and thickness measurements [42]. Such structural studies apply-
ing SD-OCT may provide surrogate markers to monitor functional rescue in translational re-
search. When observed with aging in our study, structural characterization of hemizygous
P23H-1 rats revealed gradual ONL thinning reaching 86% at 6-months of age, consistent with
histology [17]. Of note, 1- and 2-month-old P23H-1 rats showed slightly different ONL thick-
ness compared to the histological data (respectively 20μm and 10μm) from the literature
(http://www.ucsfeye.net/mlavailRDratmodels.shtml). Difference between SD-OCT and histolo-
gy measurements were also described on the same animals, but good correlation in the decreas-
ing values makes this technique interesting for monitoring [41]. Moreover, while the
degeneration seems to be slowed herein, ONL thicknesses reached comparable values. Animal
housing conditions such as light intensity and feeding were different between this and other
studies, and may also explain an initially slower degeneration documented in the present study
[43–46]. In a recent study, SD-OCT and retinal thickness measurements on histology were as-
sessed in 4-months old pigmented hemizygous P23H rats [41]. These animals were obtained by
crossing homozygous P23H-1 with Long Evans rats to more closely resemble the human disease
providing that albino rodents are more sensitive to photic trauma [47]. The 4-months old pig-
mented hemizygous P23H-1 andWT rats showed less degeneration than the 3-months old albi-
no hemizygous P23H-1 andWT albino rats in the present study and their pigmented status
could account for this difference. However, the difference in genetic background brought by
crossing may also induce variations in the course of the disease [48, 49]. Furthermore, patients
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with a P23Hmutation show regional distribution of retinal degeneration [50, 51]. In the P23H
mouse, if dark reared, photoreceptor cell death was uniformly distributed across the retina, but
when raised in cyclic light conditions, the density of apoptotic cells was greater, particularly in
the inferior region of the retina [52], the region most severely affected in patients with the P23H
mutation [50]. Photoreceptor degeneration was also accelerated by light exposure. Regional dif-
ferences were not observed in our study on hemizygous P23H-1 nor on pigmented hemizygous
P23H-1 rats [41] and one reason may be artificial light conditions in which they were raised. In-
terestingly, our study also demonstrates inner retinal abnormalities with no change in overall
inner retinal thickness with age. Moreover, inner retinal abnormalities were described by OCT
in regions where the ONL was thinned in patients with the P23Hmutation [53]. Here we
showed that hemizygous P23H-1 rats OPL thickness decreased dramatically with aging. This
result is consistent with observations obtained on synaptic complexes by immunohistochemis-
try, where dendrites of bipolar cells were found less profuse in hemizygous albino and pig-
mented P23H-1 compared to WT, especially with aging [18, 41]. Synaptic connectivity of
horizontal cells also changed after 3-months of age, with their dendrites being atrophied and
condensed [41]. INL thickness composed of nuclei of bipolar, horizontal and amacrine cells,
showed an initial decrease of 1μm in hemizygous P23H-1 compared to WT rats. With aging, no
other difference appeared in the thickness of both hemizygous P23H-1 andWT rat INL. Immu-
nohistochemistry on hemizygous albino P23H-1 rats showed that bipolar cell bodies were
smaller at 40 days of age and confined to a single layer adjacent to the OPL and decrease in
number between 5- and 9-months of age [18]. On pigmented hemizygous P23H-1 rats cell bod-
ies were smaller after 2-months of age for horizontal cells and rod and cones bipolar cells, with
a reduction in number particularly after 6-months of age [41]. These differences were not com-
pared to the age-matched pigmentedWT rats. We observed similar decreases by SD-OCT on
albinoWT and hemizygous P23H-1 rats, the role of the albino background on this degeneration
remains also unclear. IPL+GCL+NFL thickness, comprising ganglion cells, their synapses with
INL cells, and their axons forming the optic nerve, was 10% thinner in hemizygous P23H-1
than in WT rats. These results were consistent with immunohistochemistry on albino hemizy-
gous P23H-1 rats, showing that ganglion cell population was initially smaller in hemizygous
P23H-1 than inWT rats, and a difference in degeneration appeared after 6 months of age [19].
Immunohistochemistry on pigmented hemizygous P23H-1 rats showed horizontal and rod bi-
polar cells axons and varicosities were reduced after 2-months of age but these differences were
not compared to the matched-aged pigmentedWT rats [18, 41]. Finally, while correlating outer
and inner retinal function (i.e., a- and b-wave parameter correlation), we find a close correlation
that may imply the absence of additional inner retinal dysfunction to photoreceptor dysfunc-
tion suggesting that structural abnormalities do not result in functional alteration. However, the
abnormalities observed in the inner retina need to be taken into account in the development of
therapies aiming at restoring photoreceptor function, such as photoreceptor transplantation
[54], subretinal implants [55], and optogenetic activation of dormant cone photoreceptor cir-
cuitry [56], as they all need functional inner retinal cells to be effective. A precise assessment
would therefore be helpful to select candidates for appropriate treatments such as implants that
could be placed either sub or epi-retinally and optogenetics that could be implemented on
cones [56], bipolar [57] or ganglion cells [58] depending of these findings.
To conclude, this study clarifies the genotype of hemizygous P23H-1 rats, by identifying
transgene sequence, numbering the gene copies and their expression. Functional and structural
phenotypic and non-invasive in vivo evaluation by ERG and SD-OCT confirm previously re-
ported functional and histological data in the literature and provide new endpoints for valida-
tion of preclinical therapeutic intervention. These results will serve as basis for the
development of novel therapies, in particular those directly targeting the gene defect.
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